Infectious Disease
Lymphatic Filariasis
0
Pipeline Programs↗
1
Active Trials↗
1
Companies Involved↗
Lymphatic Filariasis is an early-stage landscape with 0 programs across 1 company. The most active players are Medicines Development for Global Health.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
9
clinical trials
Completed7 · 78%
Withdrawn1 · 11%
Not yet recruiting1 · 11%
Clinical Trials
Trial Activity
9 trials
Doxycycline to Treat Mansonella Perstans Infection in Patients With and Without Lymphatic Filariasis
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00340691·1,500 enrolled
Effect of Albendazole Dose on Treatment of Lymphatic Filariasis
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00511004·40 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)